Plain-English translation of NCT06586593 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether giving patients immune-boosting medications (anti-PD1 or anti-PD1 combined with anti-CTLA-4) before surgery can help treat advanced melanoma that is still operable. The goal is to see how well the medication works and how well patients tolerate it, by measuring how much of the cancer is destroyed before the surgery takes place.
Doctors know that immune-boosting treatments can help fight melanoma, but they want to understand whether giving this treatment before surgery—rather than after—can improve outcomes and help more patients respond well to treatment.
You likely qualify if…
You likely don't qualify if…
You will receive immune-boosting medications as planned by your medical team, and your doctors will carefully monitor how well the treatment is working using imaging scans or tissue biopsies. The study will track whether you go on to have surgery and how much the cancer has responded to the medication. Even if your surgery is cancelled due to the cancer disappearing completely, getting much worse, or your own choice, you can still participate in the study.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
France